

Annual General Meeting in Forward Pharma A/S

NOTICE TO CONVENE ANNUAL GENERAL MEETING

The annual general meeting in Forward Pharma A/S will be held on

13 May 2025 at 2.00 pm (CET)

at the offices of Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark.

AGENDA

- (a) The liquidator's report on the company's activities in the past financial year
- (b) Presentation and adoption of the audited annual report
- (c) Distribution of profit according to the adopted annual report
- (d) Discharge of the board of directors and the management board
- (e) Appointment of auditor

THE AGENDA AND THE COMPLETE PROPOSED RESOLUTIONS

Item (b):

The liquidator proposes that the audited annual report for 2024 is adopted by the general meeting.

Item (c):

The liquidator proposes that the result for the accounting year 2024 be carried forward by transfer to the next financial year.

Item (d):

The liquidator proposes that the board of directors and the management board.

Item (e):

According to clause 13.1 of the articles of association, the company's auditor is elected for a term of one year. The liquidator proposes to re-elect PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR-no. 33771231.

Additional information

Majority requirements

All the proposal under agenda item (b) – (e) may be adopted by a simple majority of votes.

Share capital

The current share capital of the company is DKK 1,014,735.62 divided into 101,473,562 shares of DKK 0.01 each. Each share of DKK 0.01 carries one vote.

Record date

The record date is 6 May 2025 end of day (CET).

Participation and voting rights

The right of a shareholder to attend and vote at a general meeting is determined by the shares held by the shareholder at the record date.

The number of shares held by each shareholder at the record date shall be calculated based on (i) the number of shares registered in the company's register of shareholders and (ii) any notification of ownership received by the company but not yet registered in the company's register of shareholders.

For practical reasons, shareholders are encouraged to vote by correspondence or submit a proxy to the liquidator in accordance with the instructions below.

The annual general meeting will be conducted in Danish. Participation is conditional on the shareholder having obtained an admission card in due time.

How to obtain an admission card

Access to the annual general meeting is conditional on the shareholder having requested an admission card by 9 May 2025 end of day (CET).

Admission cards for the annual general meeting may be obtained by:

- returning the attached request for admission card form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Attn. Kristian Bojsen.

How to submit a proxy

Proxies shall be submitted by 12 May 2025 end of day (CET).

Voting instructions by proxy may be completed and submitted by:

- returning the attached proxy form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Attn. Kristian Bojsen.

From shareholders unable to attend the annual general meeting, the liquidator would appreciate receiving a proxy to exercise the voting rights attached to the shares to know the shareholders' view on the respective items on the agenda.

According to Danish law, a proxy issued to the liquidator for the annual general meeting is only valid if it is in writing and dated.

How to vote by correspondence

Shareholders may vote by correspondence no later than 12 May 2025 end of day (CET) by:

- returning the attached voting by correspondence form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Attn. Kristian Bojsen.

Votes by correspondence cannot be withdrawn.

Information on the website

Further information on the general meeting will be available on www.forward-pharma.com → 'Investors' until and including the date of the annual general meeting, including:

- The notice convening the general meeting.
- Outline of the total number of shares and voting rights on the date of the notice.
- The agenda, the complete proposals, and the annual report for 2024.
- The forms to be used for voting by proxy or voting by correspondence.

28 April 2025

The liquidator of Forward Pharma A/S